Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Source: SeekingAlpha
2025-06-06 11:09:17 ET
Investment Overview
When I last covered Autolus Therapeutics plc ( AUTL ) for Seeking Alpha back in September last year, it was to make a Bull case for its shares, based on the UK-based biotech's upcoming PDUFA date for its autologous CAR-T cell therapy, obecabtagene autoleucel ("obe-cel"), in patients with relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (B-ALL)....
Read the full article on Seeking Alpha
For further details see:
Autolus: A Buy Before Key Data Readout, Potential Expansion Into Autoimmune Market
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
22.54% G/L:
$1.93 Last:
4,124,476 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
